Overview

The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients

Status:
Unknown status

Trial end date:
2010-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to verify the possible effects of OMACOR(omega-3 fatty acid) on the percentage change of small dense LDL fraction in type 2 diabetic patients with combined hyperlipidemia, we perform open-label prospective randomized multi-institutional phase IV study.

Phase:

Phase 4

Details

Lead Sponsor:

Inje University

Collaborator:

Kuhnil Pharmaceutical Co., Ltd.